Active multiple myeloma suppresses and typically eliminates coexisting MGUS

John Campbell; Jennifer Heaney; Sankalp Pandya; Zaheer Afzal; Martin F Kaiser; Roger G Owen; J Anthony Child; Walter M Gregory; Gareth J Morgan; Graham H Jackson; Christopher Bunce; Mark Drayson

doi:10.1038/bjc.2017.229

Active multiple myeloma suppresses and typically eliminates coexisting MGUS

John Campbell, Jennifer Heaney, Sankalp Pandya, Zaheer Afzal, Martin F Kaiser, Roger G Owen, J Anthony Child, Walter M Gregory, Gareth J Morgan, Graham H Jackson, Christopher Bunce, Mark Drayson

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

152 Downloads (Pure)

Abstract

Background: Myeloma is consistently preceded by premalignant monoclonal gammopathy of undetermined significance (MGUS). In >5% of MGUS patients there is a second MGUS clone (biclonal gammopathy of undetermined significance; BGUS), yet, at myeloma diagnosis, presentation of biclonal gammopathy myeloma (BGMy) is considered less frequent, implying that myeloma eradicates coexisting MGUS.
Methods: In the largest study of its kind, we assessed BGMy frequency amongst 6399 newly diagnosed myeloma patients enrolled in recent UK clinical trials.results: Compared to expected prevalence (i.e., >5% of MGUS have BGUS), only 58 of 6399 (0.91%) newly diagnosed myeloma patients had BGMy, indicating myeloma typically eliminates coexistent MGUS. In these 58 BGMy cases, the MGUS plasma cell clone was greatly suppressed in size compared to typical levels observed in conventional MGUS; contrarily, the MGUS clone did not inhibit the myeloma plasma cell clone in BGMy.
Conclusion: Myeloma eliminates the majority of competing MGUS, and when it does not, the MGUS clone is substantially reduced in size.

Original language	English
Pages (from-to)	835-839
Journal	British Journal of Cancer
Volume	117
Early online date	20 Jul 2017
DOIs	https://doi.org/10.1038/bjc.2017.229
Publication status	E-pub ahead of print - 20 Jul 2017

Keywords

myeloma
MGUS
biclonal gammopathy
plasma cells
immunoglobulins
M proteins

Access to Document

10.1038/bjc.2017.229Licence: None: All rights reserved

Campbell_et_al_Active_multiple_myeloma_suppresses_BJC_2017
Copyright: 2017 Cancer Research UK. All rights reserved 0007 – 0920/17 10.1038/bjc.2017.229
Final published version, 135 KBLicence: Creative Commons: Attribution-NonCommercial-ShareAlike (CC BY-NC-SA)

http://www.nature.com/bjc/journal/v117/n6/full/bjc2017229a.htmlLicence: None: All rights reserved

Cite this

@article{7de41c36a9de42c9b9de8eae3c71c5f3,

title = "Active multiple myeloma suppresses and typically eliminates coexisting MGUS",

abstract = "Background: Myeloma is consistently preceded by premalignant monoclonal gammopathy of undetermined significance (MGUS). In >5% of MGUS patients there is a second MGUS clone (biclonal gammopathy of undetermined significance; BGUS), yet, at myeloma diagnosis, presentation of biclonal gammopathy myeloma (BGMy) is considered less frequent, implying that myeloma eradicates coexisting MGUS.Methods: In the largest study of its kind, we assessed BGMy frequency amongst 6399 newly diagnosed myeloma patients enrolled in recent UK clinical trials.results: Compared to expected prevalence (i.e., >5% of MGUS have BGUS), only 58 of 6399 (0.91%) newly diagnosed myeloma patients had BGMy, indicating myeloma typically eliminates coexistent MGUS. In these 58 BGMy cases, the MGUS plasma cell clone was greatly suppressed in size compared to typical levels observed in conventional MGUS; contrarily, the MGUS clone did not inhibit the myeloma plasma cell clone in BGMy.Conclusion: Myeloma eliminates the majority of competing MGUS, and when it does not, the MGUS clone is substantially reduced in size.",

keywords = "myeloma , MGUS , biclonal gammopathy , plasma cells , immunoglobulins , M proteins",

author = "John Campbell and Jennifer Heaney and Sankalp Pandya and Zaheer Afzal and Kaiser, {Martin F} and Owen, {Roger G} and Child, {J Anthony} and Gregory, {Walter M} and Morgan, {Gareth J} and Jackson, {Graham H} and Christopher Bunce and Mark Drayson",

year = "2017",

month = jul,

day = "20",

doi = "10.1038/bjc.2017.229",

language = "English",

volume = "117",

pages = "835--839",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Cancer Research UK",

}

TY - JOUR

T1 - Active multiple myeloma suppresses and typically eliminates coexisting MGUS

AU - Campbell, John

AU - Heaney, Jennifer

AU - Pandya, Sankalp

AU - Afzal, Zaheer

AU - Kaiser, Martin F

AU - Owen, Roger G

AU - Child, J Anthony

AU - Gregory, Walter M

AU - Morgan, Gareth J

AU - Jackson, Graham H

AU - Bunce, Christopher

AU - Drayson, Mark

PY - 2017/7/20

Y1 - 2017/7/20

N2 - Background: Myeloma is consistently preceded by premalignant monoclonal gammopathy of undetermined significance (MGUS). In >5% of MGUS patients there is a second MGUS clone (biclonal gammopathy of undetermined significance; BGUS), yet, at myeloma diagnosis, presentation of biclonal gammopathy myeloma (BGMy) is considered less frequent, implying that myeloma eradicates coexisting MGUS.Methods: In the largest study of its kind, we assessed BGMy frequency amongst 6399 newly diagnosed myeloma patients enrolled in recent UK clinical trials.results: Compared to expected prevalence (i.e., >5% of MGUS have BGUS), only 58 of 6399 (0.91%) newly diagnosed myeloma patients had BGMy, indicating myeloma typically eliminates coexistent MGUS. In these 58 BGMy cases, the MGUS plasma cell clone was greatly suppressed in size compared to typical levels observed in conventional MGUS; contrarily, the MGUS clone did not inhibit the myeloma plasma cell clone in BGMy.Conclusion: Myeloma eliminates the majority of competing MGUS, and when it does not, the MGUS clone is substantially reduced in size.

AB - Background: Myeloma is consistently preceded by premalignant monoclonal gammopathy of undetermined significance (MGUS). In >5% of MGUS patients there is a second MGUS clone (biclonal gammopathy of undetermined significance; BGUS), yet, at myeloma diagnosis, presentation of biclonal gammopathy myeloma (BGMy) is considered less frequent, implying that myeloma eradicates coexisting MGUS.Methods: In the largest study of its kind, we assessed BGMy frequency amongst 6399 newly diagnosed myeloma patients enrolled in recent UK clinical trials.results: Compared to expected prevalence (i.e., >5% of MGUS have BGUS), only 58 of 6399 (0.91%) newly diagnosed myeloma patients had BGMy, indicating myeloma typically eliminates coexistent MGUS. In these 58 BGMy cases, the MGUS plasma cell clone was greatly suppressed in size compared to typical levels observed in conventional MGUS; contrarily, the MGUS clone did not inhibit the myeloma plasma cell clone in BGMy.Conclusion: Myeloma eliminates the majority of competing MGUS, and when it does not, the MGUS clone is substantially reduced in size.

KW - myeloma

KW - MGUS

KW - biclonal gammopathy

KW - plasma cells

KW - immunoglobulins

KW - M proteins

U2 - 10.1038/bjc.2017.229

DO - 10.1038/bjc.2017.229

M3 - Article

SN - 0007-0920

VL - 117

SP - 835

EP - 839

JO - British Journal of Cancer

JF - British Journal of Cancer

ER -

Active multiple myeloma suppresses and typically eliminates coexisting MGUS

Abstract

Keywords

Access to Document

Fingerprint

Cite this